Gastrointestinal stromal tumours (GISTs): A clinicopathological and molecular study of 66 cases

Pathology

Volumn 37, Issue 1, 2005, Pages 22-31

  Koay, M H Eleanor ^a   Goh, Yu Wei ^b   Iacopetta, Barry ^c   Grieu, Fabienne ^c   Segal, Amanda ^a   Sterrett, Gregory F ^a   Platten, Michael ^a   Spagnolo, Dominic V ^a,d  

^a PathCentre ^*  (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PathCentre   (Australia)

Author keywords

c kit; c kit mutation; CD117; Gastrointestinal stromal tumor; Gastrointestinal stromal tumour; GIST; Imatinib mesylate; PCR SSCP; Polymerase chain reaction and single strand conformation polymorphism analysis; STI 571

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD34 ANTIGEN; KERATIN; PROTEIN S 100; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; AUSTRALIA; CANCER SURVIVAL; CELL STRUCTURE; EPITHELIOID CELL; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; MORTALITY; ONCOGENE C KIT; OUTCOMES RESEARCH; PATHOLOGY; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SPINDLE CELL; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION; TUMOR NECROSIS;

EID: 14644404874     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020400023628     Document Type: Article

References (67)

1. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-69.
2. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001; 193: 505-10.
3. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998; 115: 1090-5.
4. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Pathol 1999; 23: 377-89.
5. Bateson EM. Histogenesis of intrapulmonary and endobronchial hamartomas and chondromas (cartilage-containing tumours): a hypothesis. J Pathol 1970; 101: 77-83.
6. Bateson EM, Hayes JA, Woo MM. Endobronchial teratoma associated with bronchiectasis and bronchiolectasis. Thorax 1968; 23: 69-76.
7. Tortella BJ, Matthews JB, Antonioli DA. Gastric autonomic nerve (GAN) tumor and extra-adrenal paraganglioma in Carney's triad. A common origin. Ann Surg 1987; 205: 221-5.
8. Eyden B, Chorneyko KA, Shanks JH, et al. Contribution of electron microscopy to understanding cellular differentiation in mesenchymal tumors of the gastrointestinal tract: a study of 82 tumours. Ultrastruct Pathol 2002; 26: 269-85.
9. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001; 8: 252-61.
10. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13: 1134-42.
11. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-34.
12. Lee JR, Joshi V, Griffin JW, et al. Gastrointestinal autonomic nerve tumor: immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001; 25: 979-87.
13. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
14. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001; 54: 96-102.
15. Sarlomo-Rikala M, Tsujimura T, Lendahl U, Miettinen M. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 2002; 110: 499-507.
16. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53-60.
17. Medeiros F, Duensing A, Hornick JL, et al. KIT negative gastrointestinal stromal tumors. Mod Pathol 2003; 16: 128A (abstr).
18. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1988; 6: 3341-51.
19. Qiu FH, Ray P, Brown K, et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C-terminus. EMBO J 1988; 7: 1003-11.
20. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-74.
21. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990; 63: 185-94.
22. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63: 213-24.
23. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12.
24. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-44.
25. Kitayama H, Kanakura Y, Furitsu T, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995; 85: 790-8.
26. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-95.
27. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000; 157: 1091-5.
28. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21.
29. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
30. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New Engl J Med 2001; 344: 1052-6.
31. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002; 347: 472-80.
32. Ma Y, Zeng S, Metcalfe DD, et al. The c-Kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-4.
33. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
34. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293-301.
35. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83.
36. Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25: 1121-33.
37. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
38. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160: 1567-72.
39. Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum. A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27: 625-41.
40. Lasota J, Dansonka-Mieszkowskia A, Stachura T, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favourable course. Mod Pathol 2003; 16: 1257-64.
41. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behaviour: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumours. Clin Cancer Res 2003; 9: 3329-37.
42. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003; 34: 1306-12.
43. Allander SV, Nupponen NN, Ringnér M, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogenous gene expression profile. Cancer Res 2001; 61: 8624-8.
44. Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 2004; 53: 235-40.
45. Segal A, Carello S, Caterina P, et al. Gastrointestinal autonomic nerve tumors: a clinicopathological, immunohistochemical and ultrastructural study of 10 cases. Pathology 1994; 26: 439-47.
46. Soong R, Iacopetta BJ. A rapid and nonisotopic method for screening and sequencing of p53 gene mutations in formalin-fixed, parrafin-embedded tumors. Mod Pathol 1997; 10: 252-8.
47. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for suvival. Ann Surg 2000; 231: 51-8.
48. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.
49. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56: 2242-50.
50. Goldblum JR. Gastrointestinal stromal tumors. A review of characteristic morphologic, immunohistochemical, and molecular genetic features. Am J Clin Pathol 2002; 117 (suppl): S49-61.
51. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32: 578-82.
52. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
53. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38: S39-S51.
54. Singer S, Rubin BP, Lux M, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-905.
55. Trupiano JK, Stewart RE, Misick C, et al. Gastric stromal tumors. A clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviours. Am J Surg Pathol 2002; 26: 705-14.
56. Miettinen M, Sarloma-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding their biology. Hum Pathol 1999; 30: 1213-20.
57. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54: 3-24.
58. Goldblum JR, Appelman HD. Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. Am J Surg Pathol 1995; 19: 71-80.
59. Brainard JA, Goldblum JR. Stromal tumors of the jejunum and ileum: a clinicopathologic study of 39 cases. Am J Surg Pathol 1997; 21: 407-16.
60. Tworek JA, Appelman HD, Singleton TP, Greenson JK. Stromal tumors of the jejunum and ileum. Mod Pathol 1997; 10: 200-9.
61. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 61: 39-48.
62. Moskaluk CA, Tian Q, Marshall CR, et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999; 18: 1897-902.
63. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78: 1633-6.
64. Sakurai S, Fukasawa T, Chong JM, et al. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999; 90: 1321-8.
65. Sakurai S, Oguni S, Hironaka M, et al. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 2001; 92: 494-8.
66. Yamaguchi M, Miyaki M, Iijima T, et al. Specific mutation in exon 11 of c-kit proto-oncogene in a malignant gastrointestinal stromal tumor of the rectum. J Gastroenterol 2000; 35: 779-83.
67. Wardelmann E, Neidt I, Bierhoff E, et al. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002; 15: 125-36.